Flare Therapeutics Inc. has synthesized peroxisome proliferator-activated receptor γ (PPARγ) inverse agonists reported to be useful for the treatment of bladder cancer.
Hitgen Ltd. has divulged NUAK family SNF1-like kinase 1 (NUAK1) and/or NUAK family SNF1-like kinase 2 (NUAK2) inhibitors reported to be useful for the treatment of cancer.
Viva Star Biosciences Ltd. has presented son of sevenless homolog 1 (SOS1)/GTPase KRAS interaction inhibitors reported to be useful for the treatment of cancer.
Cambridge Enterprise Ltd. has synthesized benzo[c][2,6]naphthyridine derivatives acting as casein kinase II isoform alpha prime (CK2α′) inhibitors reported to be useful for the treatment of cancer, diabetes, ischemia, neurodegeneration, viral infections cardiovascular and inflammatory disorders, among others.
Verismo Therapeutics Inc. has received U.S. orphan drug designation from the FDA for Synkir-110 for the treatment of patients with mesothelin-expressing mesotheliomas.
Sengine Precision Medicine Inc. is conducting a study utilizing its high-throughput patient-derived organoid drug screening technology to identify novel therapeutic targets in progressive anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC).
Zai Lab Ltd. has agreed to pay $30 million up front to in-license from Seagen Inc. exclusive rights to the antibody-drug conjugate (ADC) Tivdak (tisotumab vedotin) in mainland China, Hong Kong, Macau and Taiwan. Seagen is also eligible to receive development, regulatory, and commercial milestone payments of undisclosed value, as well as tiered royalties on net sales of the drug in Zai’s territory.
Pheon Therapeutics Ltd. is working to bring next-generation antibody-drug conjugate (ADC) payloads and enhanced tolerability into the clinic after closing a $68 million series A.
The University of Michigan has synthesized new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked estrogen receptor (ER) targeting moiety reported to be useful for the treatment of breast cancer.
The State University of New York has presented new antibody-drug conjugates (ADCs) consisting of trastuzumab antibody targeting human epidermal growth factor receptor 2 (HER2) covalently linked to Toll-like receptor 7 (TLR7) and/or TLR8 agonists through a linker reported to be useful for the treatment of cancer and infections.
RSS
